GenAns Biotech raises hundreds of millions of yuan in Series A for gene therapies
What's the deal? GenAns BiotechDealroom has a profile for this one. Try Dealroom →, a gene therapy company focused on central nervous system (CNS) and ophthalmic diseases, has closed a Series A round worth hundreds of millions of yuan. Taiping Healthcare FundDealroom has a profile for this one. Try Dealroom → led the round, with returning shareholder Huatai Zijin's fund following on.
Who else joined? Gaorong Capital and several other new and existing shareholders also participated in the round, which was announced in July 2026.
What's the endgame? The company develops gene-based treatments for CNS disorders and eye diseases, areas where conventional drugs often struggle to reach or address the underlying cause.
The signal: The backing from a healthcare-focused fund alongside repeat investors points to continued investor appetite for gene therapy platforms targeting hard-to-treat conditions.
Read more: IT桔子
Image credit: National Institutes of Health (NIH)
